For a long time confined to operating rooms for its pro-coagulant properties, Tranexamic Acid (TXA) is now establishing itself as the “game-changing” active ingredient in aesthetic medicine clinics.
AN UNEXPECTED HISTORY: FROM COAGULANT TO ANTI-PIGMENT
The origin of TXA is purely medical. As a synthetic derivative of the amino acid lysine, it has proven itself for decades as a powerful antifibrinolytic agent. Patients treated orally for bleeding saw their melasma fade dramatically. Today, in topical application, it has become the best targeted response for treating hyperpigmentation and post-procedure inflammation.
TXA + Niacinamide: A Unique Treatment for Hyperpigmentation
The combination of 5% Tranexamic Acid (TXA) and 10% Niacinamide is now recognised as one of the most powerful duos in aesthetic dermatology for the treatment of hyperpigmentation. While TXA inhibits tyrosinase and blocks the inflammatory and vascular cascades as well as melanocyte activation (via the plasmin pathway), Niacinamide prevents the transfer of melanin to keratinocytes.
This provides a unique dual mechanism targeting the hyperpigmentation process, brought to you by DERMEDEN Laboratories.
DERMEDEN MELAFLASH TXA+NIA: Proven by Clinical Evidence
Several in vivo clinical studies involving subjects with pigmentation disorders, including melasma, solar lentigines, and post-inflammatory hyperpigmentation (PIH), have demonstrated the safety and efficacy of the DERMEDEN Laboratories MELAFLASH protocol (5% TXA, 10% Niacinamide). A safe, effective, and easy-to-implement solution, with no limitations on treatment frequency or duration and suitable for all Fitzpatrick skin types.
For more information: www.DERMEDEN.com
